deltatrials
Completed PHASE2 NCT01822249

Phase 2 Study of EPI-743 for Treatment of Rett Syndrome

A Phase 2A Randomized, Placebo Controlled Trial of EPI-743 in Children With Rett Syndrome

Sponsor: Edison Pharmaceuticals Inc

Conditions Rett Syndrome
Interventions EPI-743 Placebo
Updated 7 times since 2017 Last updated: Jul 23, 2018 Started: Jan 31, 2013 Primary completion: Dec 31, 2013 Completion: Jan 31, 2014

A PHASE2 clinical study on Rett Syndrome, this trial is completed. The trial is conducted by Edison Pharmaceuticals Inc and has accumulated 7 data snapshots since 2013. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Change History

7 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE2

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE2

  3. Jan 2021 — Jul 2024 [monthly]

    Completed PHASE2

  4. Aug 2018 — Jan 2021 [monthly]

    Completed PHASE2

  5. Jun 2018 — Aug 2018 [monthly]

    Completed PHASE2

▶ Show 2 earlier versions

  1. Feb 2017 — Jun 2018 [monthly]

    Completed PHASE2

  2. Jan 2017 — Feb 2017 [monthly]

    Completed PHASE2

    First recorded

Jan 2013

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Edison Pharmaceuticals Inc
Data source: Edison Pharmaceuticals Inc

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

  • • Siena, Italy